An open label, phase IIa, safety study of the active implantable (radiological) medical device 32P BioSilicon, administered intratumourally to patients with advanced, unresectable pancreatic cancer, in addition to standard intravenous Gemci

  • Palmer, Daniel (Principal Investigator)

Project Details

Short titleAn open label, phase IIa, safety study of the active implantable (radiological) medical device 32P BioSilicon, administered intratumourally to patients with advanced, unresectable pancreatic cancer, in addition to standard intravenous Gemci
StatusFinished
Effective start/end date1/07/07 → 31/10/08

Funding

  • Queen Elizabeth Hospital